Article
Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells.
Journal of cellular physiology - 1 Jul 2003
Xu Yue, Iyengar Sunita, Roberts Richard L, Shappell Scott B, Peehl Donna M
Abstract excerpt
BRL 49653 (rosiglitazone) is a thiazolidinedione anti-diabetic drug that activates the nuclear receptor, peroxisome proliferator-activated receptor gamma (PPARgamma). Pilot clinical trials have shown evidence of therapeutic activity of PPARgamma agonists against prostate cancer. To more effectively use PPARgamma ligands to treat this common and generally chemo-resistant type of cancer, it will be necessary to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
